Shanghai Fosun Buys Majority Share Of Saladax Devices For $22.5 Million
This article was originally published in PharmAsia News
Executive Summary
Shanghai Fosun Pharmaceutical said it has bought a majority share of U.S. based Saladax Biomedical for $22.5 million.